No Data
No Data
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
Express News | Trevi Therapeutics Inc - Topline Results Expected in First Half of 2025
Express News | Trevi Therapeutics Completes Enrollment for Phase 2B Coral Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Astrana Health (ASTH) and Penumbra (PEN)